dr. antonarakis on ar-v7 and resistance to ar-targeting agents in mcrpc
Published 9 years ago • 201 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:20
dr. antonarakis on ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer
-
1:32
dr. antonarakis discusses ar-v7 and response to taxanes in men with mcrpc
-
1:04
dr. emmanuel s. antonarakis on the future of the ar-v7 biomarker in prostate cancer
-
6:29
ar-v7 and drug resistance
-
2:34
ar-v7 as a biomarker in crpc
-
6:56
ar-v7 testing for men with advanced stage prostate cancer
-
2:10
preserve the nerves ! what to know about nerve sparing
-
24:59
prostate cancer: diagnosis and treatment options. dr. aaron berger, associated urological specialist
-
0:42
dr. rathkopf on ar-v7 biomarker in prostate cancer
-
1:51
tenascin-c activated src regulates ar-v7 related to treatment resistance in prostate cancer
-
1:12
antonarakis: ar-v7, taxane response in mcrpc
-
8:09
treating mcrpc with newer hormonal agents
-
3:11
prostate cancer: advice for oncologists on ar-v7 testing
-
1:09
dr. dreicer on resistance to antiandrogen therapy in prostate cancer
-
7:46
prostate cancer: validation of ar-v7 testing
-
3:36
john’s hopkins ar-v7 test in prostate
-
6:18
prostate cancer: discovery and importance of ar-v7
-
4:27
dr. emmanuel antonarakis on the unique attributes of the taxynergy study
-
5:34
multidisciplinary care for prostate cancer and ar-v7 status
-
6:16
evolution of treatment for metastatic castration-resistant prostate cancer
-
3:04
prostate cancer: educating physicians about ar-v7 testing
-
9:12
prostate cancer: epic sciences ar-v7 test